Cencora (COR) Competitors $241.47 -1.99 (-0.82%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$241.43 -0.04 (-0.02%) As of 02/21/2025 05:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends COR vs. MCK, CAH, HSIC, PDCO, OMI, HLF, NUS, COSM, HWH, and MEDSShould you be buying Cencora stock or one of its competitors? The main competitors of Cencora include McKesson (MCK), Cardinal Health (CAH), Henry Schein (HSIC), Patterson Companies (PDCO), Owens & Minor (OMI), Herbalife (HLF), Nu Skin Enterprises (NUS), Cosmos Health (COSM), HWH International (HWH), and TRxADE HEALTH (MEDS). Cencora vs. McKesson Cardinal Health Henry Schein Patterson Companies Owens & Minor Herbalife Nu Skin Enterprises Cosmos Health HWH International TRxADE HEALTH Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, community ranking, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation. Is COR or MCK a better dividend stock? Cencora pays an annual dividend of $2.20 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.84 per share and has a dividend yield of 0.5%. Cencora pays out 31.3% of its earnings in the form of a dividend. McKesson pays out 13.0% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 15 consecutive years and McKesson has raised its dividend for 17 consecutive years. Is COR or MCK more profitable? McKesson has a net margin of 0.82% compared to Cencora's net margin of 0.46%. Cencora's return on equity of 328.62% beat McKesson's return on equity.Company Net Margins Return on Equity Return on Assets Cencora0.46% 328.62% 4.23% McKesson 0.82%-181.26%5.34% Do institutionals & insiders have more ownership in COR or MCK? 97.5% of Cencora shares are held by institutional investors. Comparatively, 85.1% of McKesson shares are held by institutional investors. 10.8% of Cencora shares are held by insiders. Comparatively, 0.1% of McKesson shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, COR or MCK? Cencora has a beta of 0.49, indicating that its stock price is 51% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.52, indicating that its stock price is 48% less volatile than the S&P 500. Which has preferable valuation and earnings, COR or MCK? McKesson has higher revenue and earnings than Cencora. McKesson is trading at a lower price-to-earnings ratio than Cencora, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCencora$293.96B0.16$1.51B$7.0334.35McKesson$308.95B0.24$3.00B$21.8427.37 Does the media prefer COR or MCK? In the previous week, McKesson had 15 more articles in the media than Cencora. MarketBeat recorded 41 mentions for McKesson and 26 mentions for Cencora. McKesson's average media sentiment score of 1.49 beat Cencora's score of 1.30 indicating that McKesson is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Cencora 22 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive McKesson 36 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer COR or MCK? McKesson received 227 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.33% of users gave McKesson an outperform vote while only 65.38% of users gave Cencora an outperform vote. CompanyUnderperformOutperformCencoraOutperform Votes74665.38% Underperform Votes39534.62% McKessonOutperform Votes97374.33% Underperform Votes33625.67% Do analysts prefer COR or MCK? Cencora currently has a consensus price target of $277.90, indicating a potential upside of 15.09%. McKesson has a consensus price target of $645.79, indicating a potential upside of 8.05%. Given Cencora's higher possible upside, analysts clearly believe Cencora is more favorable than McKesson.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cencora 0 Sell rating(s) 2 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.82McKesson 0 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.94 SummaryMcKesson beats Cencora on 16 of the 22 factors compared between the two stocks. Get Cencora News Delivered to You Automatically Sign up to receive the latest news and ratings for COR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart COR vs. The Competition Export to ExcelMetricCencoraDrugs, proprietaries, & sundries IndustryMedical SectorNYSE ExchangeMarket Cap$46.83B$21.59B$5.77B$20.02BDividend Yield0.90%1.37%4.78%3.65%P/E Ratio34.3512.1826.4934.88Price / Sales0.161.40449.1515.59Price / Cash12.3512.7944.0420.85Price / Book129.1328.607.634.92Net Income$1.51B$872.92M$3.18B$1.02B7 Day Performance-0.64%2.93%-1.82%-1.05%1 Month Performance-1.53%-3.03%0.22%-1.39%1 Year Performance3.43%-12.49%17.49%13.93% Cencora Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CORCencora4.4143 of 5 stars$241.47-0.8%$277.90+15.1%+3.4%$46.83B$293.96B34.3546,000Positive NewsMCKMcKesson4.7097 of 5 stars$593.82-1.4%$645.79+8.8%+17.8%$75.38B$308.95B27.1951,000Insider TradePositive NewsCAHCardinal Health4.7844 of 5 stars$126.35-0.3%$136.87+8.3%+20.2%$30.52B$226.83B23.5748,900Positive NewsHSICHenry Schein3.8649 of 5 stars$76.00-2.1%$80.09+5.4%+2.9%$9.48B$12.34B31.2825,000Upcoming EarningsPDCOPatterson Companies4.291 of 5 stars$31.030.0%$26.57-14.4%+11.6%$2.74B$6.57B18.157,600Upcoming EarningsOMIOwens & Minor4.5972 of 5 stars$7.45-3.8%$16.79+125.5%-71.4%$574.08M$10.33B-11.4513,700Upcoming EarningsAnalyst RevisionHLFHerbalife3.4656 of 5 stars$5.59+7.0%$9.90+77.2%-1.3%$563.13M$5.00B6.579,200Earnings ReportAnalyst ForecastOptions VolumeNews CoverageGap DownHigh Trading VolumeNUSNu Skin Enterprises3.1216 of 5 stars$7.54+17.4%$6.88-8.8%-39.9%$374.57M$1.73B-3.643,700Analyst RevisionHigh Trading VolumeCOSMCosmos Health1.8878 of 5 stars$0.62-3.2%N/A-23.6%$14.41M$53.38M-0.25100HWHHWH InternationalN/A$0.32-4.2%N/A-78.0%$10.06MN/A0.00N/ANews CoverageNegative NewsGap DownMEDSTRxADE HEALTHN/A$3.15-0.7%N/A-66.3%$4.43M$7.45M0.0050Gap Up Related Companies and Tools Related Companies MCK Competitors CAH Competitors HSIC Competitors PDCO Competitors OMI Competitors HLF Competitors NUS Competitors COSM Competitors HWH Competitors MEDS Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:COR) was last updated on 2/22/2025 by MarketBeat.com Staff From Our Partners[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredWhy Buffett and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cencora, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cencora With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.